# US 2009/0024105 A1 · Methods for the Treatment of Sepsis and Sepsis-Associated Cardiac Dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0024105 A1
- Document ID: US20090024105A1
- Status: Published application
- Kind: A1
- Application number: 11/816,230
- Filed: 2006-02-14
- Published: 2009-01-22
- Earliest claimed: 2005-02-14
- Assignees: The Children's Hospital of Philadelphia; The Trustee of the University of Pennsylvania
- Inventors: Richard J. Levy; Clifford S. Deutschman
- Web page: https://patentgrep.com/patent/US20090024105A1

## CPC

- A61K 38/41: Porphyrin- or corrin-ring-containing peptides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods for the treatment of sepsis related cardiac dysfunction are disclosed.

## Claims

### Claim 1

A method for the treatment of sepsis and/or sepsis-associated cardiac dysfunction in a patient in need thereof comprising administration of an effective amount of cytochrome c.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cytochrome c is administered intravenously.

### Claim 3 (depends on 1)

The method of claim 1, further comprising administration of an amount of ascorbic acid effective to reduce said cytochrome c.

### Claim 4 (depends on 1)

The method of claim 1, wherein said method is for the treatment of sepsis associated with a condition selected from the group consisting of systemic inflammatory response syndrome, (SIRS), and multiple organ dysfunction syndrome (MODS).

### Claim 5 (depends on 1)

The of claim 1 wherein said cardiac dysfunction is associated with a condition selected from the group consisting of burns, trauma, hemorrhage, cardiopulmonary bypass, hypoxia and ischemia, cardiomyopathies, smoke inhalation, carbon monoxide poisoning, inborn errors of metabolism, mitochondriopathies, and induction of stasis or hibernation.

### Claim 6 (depends on 3)

The method of claim 3, wherein said cytochrome C is reduced prior to administration.

### Claim 7 (depends on 1)

The method of claim 1, wherein said cytochrome c is in reduced form.

### Claim 8 (depends on 7)

The method of claim 7, wherein the reduced cytochrome c is ferrocytochrome c.

### Claim 9

A method for identifying agents having efficacy in the treatment of sepsis-associated cardiac dysfunction comprising
a) providing a septic subject,
b) administering a test agent to said subject, and
c) determining whether said agent improves cardiac function in said septic subject, said improvement comprising restoration of oxidative capacity.

### Claim 10 (depends on 9)

The method of claim 9, wherein said restoration of oxidative capacity comprises a process selected from the group consisting of at least one of a decrease in myocardial glucose uptake, a decrease in steady-state levels of myocardial GLUT4, and a decrease in glycogen deposition.
